Parmax Pharma Ltd.
Fundamentals
- Market cap
- ₹28.09 cr
- ROE
- 105.30%
- Debt / equity
- -4.07
- 52-week range
- 22.60 — 73.61
Company snapshot
Parmax Pharma Ltd.
Pharmaceuticals
₹28 cr
Latest quarter · Mar 2026
Sales₹3 cr
Net profit−₹1 cr
Op. margin−46.8%
EPS−₹1.56
Strength & growth
Debt / equity-4.07×
Current ratio0.77×
Sales CAGR+70.0%
The timeline — 4 notes on Parmax Pharma Ltd.
June 2026
- 09 Jun 26 · 8:53 AM IST Alert Alert · M&A · Micro cap
Parmax Pharma's new owners are taking over. They're paying ₹42.80 a share.
Dhiren and Sunil Shah, with a consortium of ten others, are paying ₹18.6 crore to take ~91% control of the struggling nano-cap, which saw revenues collapse 57% and losses widen.
- 08 Jun 26 · 3:24 PM IST Alert Alert · Micro cap
Parmax Pharma raises ₹19.28 cr, hands control to 14 new investors
The raise is worth 113% of the company's ₹17 cr market cap. The new allottees will become majority owners.
- 03 Jun 26 · 9:18 PM IST Lead Lead · Micro cap
Parmax Pharma turns to a preferential issue after a 57% revenue crash.
A nano-cap with a ₹14 crore market cap, ₹4.16 crore in annual losses, and auditors flagging the Managing Director's fund use is seeking fresh equity.
- 03 Jun 26 · 6:47 PM IST Brief Brief · Earnings · Micro cap
Parmax Pharma revenue halved, auditors flag MD's use of company funds
FY26 revenue fell 57% to ₹12.11 crore as auditors qualified the accounts over unauthorized mutual fund purchases in the managing director's name.